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Abstract
Osteoporosis is one of the most common bone pathologies, which are characterized by a decrease in bone mass. It is well
established that bone mass, which results from a balanced bone formation and bone resorption, is regulated by many
hormonal, environmental and genetic factors. Here we report that the immune semaphorin 4D (Sema4D) is a novel factor
controlling bone resorption. Sema4D-deficient primary osteoclasts showed impaired spreading, adhesion, migration and
resorption due to altered ß3 integrin sub-unit downstream signaling. In apparent accordance with these in vitro results,
Sema4D deletion in sexually mature female mice led to a high bone mass phenotype due to defective bone resorption by
osteoclasts. Mutant males, however, displayed normal bone mass and the female osteopetrotic phenotype was only
detected at the onset of sexual maturity, indicating that, in vivo, this intrinsic osteoclast defect might be overcome in these
mice. Using bone marrow cross transplantation, we confirmed that Sema4D controls bone resorption through an indirect
mechanism. In addition, we show that Sema4D 2/2 mice were less fertile than their WT littermates. A decrease in Gnrh1
hypothalamic expression and a reduced number of ovarian follicles can explain this attenuated fertility. Interestingly,
ovariectomy abrogated the bone resorption phenotype in Sema4D 2/2 mice, providing the evidence that the observed
high bone mass phenotype is strictly dependent on ovarian function. Altogether, this study reveals that, in vivo, Sema4D is
an indirect regulator of bone resorption, which acts via its effect on reproductive function.
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Introduction
Osteoporosis is one of the most common bone pathology, which
is characterized by a decrease in bone mass, leading to an
increased fracture risk. Therefore, slowing the osteoporosis
progression has become a major health issue in the aging
population of the northern hemisphere. Reproductive hormones
fluctuations have a well-established role in osteoporosis. In early
menopause, the acute phase of estrogens deficiency is associated
with an increased bone loss [1]. However, clinical studies, have
provided evidence that the etiology of this disease is more complex
than just a question of estrogen withdrawal and that overall bone
mass is influenced by many environmental, but also genetic factors
[2]. Among those factors, several studies have suggested a role for
semaphorin family members in the control of bone mass. Sema3B
expression in osteoblasts is induced by vitamin D3 and its
deficiency leads to osteopenia, secondary to increased osteoclas-
togenesis [3]. Sema7A is also expressed in bone cells [4]. Sema7A as
well as Plexin A2 (Sema 3A receptor) polymorphisms have been
associated with decreased bone mineral density and increased
fracture risk in postmenopausal Korean woman [5,6]. Deficiency
in Plexin A1, the Sema6D receptor, leads to increased bone mass due
to a defect in osteoclast differentiation [7].
Sema4D is a membrane-bound class 4 semaphorin that was first
identified in the immune synapse where it mediates cell-to-cell
interactions and regulates the immune response [8]. Sema4D is in
fact expressed in other tissues including platelets, ovaries and the
nervous system, where it has several functions [9]. Sema4D
stimulates both in vitro and in vivo angiogenesis [10,11]. In the
nervous system, Sema4D is involved in neuronal migration and
neurite outgrowth. For example, Sema4D has been shown to
regulate gonadotropin hormone-releasing hormone-1 (Gnrh1)
positive neuron migration through the PlexinB1-Met complex
[12,13]. Sema4D acts on another level of the hypothalamic-
hypophyseal-ovarian axis, as ex vivo data has shown that Sema4D is
involved in mouse ovary follicle maturation [14]. Interestingly,
structural studies have revealed strong similarities between the
Sema4D homodimer and the aVß3 integrin heterodimer, which is
the most abundant integrin receptor expressed in bone resorbing
osteoclasts [15]. aVß3 integrin plays a major role in osteoclast
function, both in vitro and in vivo. For instance, integrin ß3 2/2
mice become progressively osteosclerotic with age due to
dysfunctional osteoclasts that fail to polarize correctly and develop
abnormal ruffled membranes [16]. In the present study, using the
loss of function approach, we addressed the question whether
Sema4D could also play a role in bone resorption.We first show that
Sema4D is expressed in osteoclasts and that like ß3integrin-deficient
osteoclasts, Sema4D 2/2 osteoclasts exhibit a resorption defect
consecutive to reduced migration and spreading. We then provide
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phenotype associated to a bone resorption defect. Interestingly this
high bone mass phenotype was not found in males and in sexually
immature female. Besides this phenotype, we showed that
Sema4D2/2 females exhibited a reproductive defect. Finally, we
demonstrate that the bone resorption phenotype does not result
from an osteoclast-specific defect but that it is strictly dependent on
Sema4D action on ovarian function. Thus Sema4D is an indirect
regulator of bone resorption that acts through its effect on the
reproductive system in females.
Results
Sema4D expressed in osteoclasts, delays osteoclasts
differenciation and affects osteoclast function
The most abundant integrin in osteoclasts is aVß3 integrin,
which plays a major role in regulating the bone resorption process
[17]. Because Sema4D homodimers share many structural
similarities with the aVß3 integrin heterodimer [15], we
hypothesized that Sema4D could have similar functions. We found
that Sema4D mRNA, as well as the protein, is expressed in pre- and
in mature primary osteoclasts (Figs. 1A–B) [18]. In contrast,
Sema4D was not detected in primary osteoblasts derived from
mouse calvaria (Fig. 1B). Moreover, FACS analysis showed that
Sema4D is expressed at the osteoclast cell membrane. We further
localized Sema4D within cytoskeletal structures by specific ß3
integrin co-immunolabeling in mature osteoclasts (Figs. 1C–D). As
expected, anti-b3 integrin labeled the podosome belt at the
periphery of mature osteoclasts and Sema4D partially colocalized
with ß3 integrin. These observations were compatible with a role
for Sema4D in osteoclast mediated bone resorption. To explore the
potential effect of Sema4D on osteoclast differentiation, we first
carried out classical in vitro primary osteoclast differentiation assays
in the presence of M-CSF and RANKL. Osteoclast differentiation
assays of WT or Sema4D-deficient bone marrow isolated precursors
revealed that differentiation was reduced in the absence of Sema4D,
as the number of osteoclasts measured in WT cultures was higher
that in Sema4D 2/2 on days 4 and 5 (Fig. 1E). In order to assess if
the reduced number of osteoclasts obtained in Sema4D2/2
cultures was due to a proliferation or a fusion defect in progenitor
cells, we first performed a proliferation test on osteoclast
precursors isolated from Sema4D 2/2 or WT bone marrow in
the presence of M-CSF. Crystal violet proliferation tests revealed
that bone-marrow derived precursors isolated from Sema4D-
deficient mice exhibited a small but statistically significant
proliferation delay at early time points, which was abrogated after
5 days in culture (Fig. 1F). This later result strongly suggested that
the fusion process had decreased, as a consequence of a slightly
lower proliferation of Sema4D 2/2 precursors. To definitively
prove that the reduced number of Sema4D osteoclasts was not due
to an intrinsic fusion defect, but to proliferation, we plated 20%
more Sema4D 2/2 precursors than WT in the presence of MCSF
and RANKL to overcome their slower proliferation rate. Under
such plating conditions, the same number of mature osteoclasts
was obtained. Indeed, they contained the same number of nuclei
as WT, showing that under such conditions the process of
differentiation was not affected by Sema4D deficiency (Fig. 1G).
These plating conditions allowed us to really compare Sema4D 2/2
and WT osteoclasts from the same differentiation stage, and have
been used all along this study.
To then test whether osteoclast function could be affected in the
absence of Sema4D, we performed resorption tests on an apatite
collagen complex (ACC) and showed that in the absence of
Sema4D, the percentage of resorbed area per osteoclast was
significantly reduced, by two fold, in the Sema4D-deficient
osteoclasts compared to WT (Fig. 2A). As resorption by osteoclasts
is a multistep process that requires adhesion, spreading, resorption
per se, and migration [19], we wanted to determine which of these
steps was affected in the absence of Sema4D. Measurements by
time-lapse video microscopy of WT and Sema4D 2/2 mature
osteoclasts (n$80) revealed that mature Sema4D-deficient osteo-
clasts migrated more slowly than WT osteoclasts (Fig. 2B). Cell
spreading was delayed in the absence of Sema4D 2/2 as cell area
was reduced during the early stages of adhesion on vitronectin.
This difference was not observed at the latest time point, indicating
that Sema4D 2/2 osteoclasts were able to make up the delay
(Fig. 2C). Altogether, these data indicate that Sema4D-deficient
osteoclasts migrate more slowly than WT and subsequently resorb
mineralized matrix less efficiently than WT osteoclasts.
Altered aVß3 integrin mediated adhesion dependent
signaling in Sema4D 2/2 osteoclasts
Osteoclast migration, adhesion and resorption are highly linked
processes. They are all promoted by dynamic cytoskeletal
reorganization, which involves aVß3 integrin-dependent signaling.
Having shown that spreading, migration and resorption are
affected in Sema4D 2/2 osteoclasts, we asked whether down-
stream signaling in response to aVb3 integrin activation could
normally occur in osteoclasts lacking Sema4D. To address this
question, we analyzed c-Src and Pyk2 phosphorylation, both
molecular components of the adhesion complex triggered by aVß3
integrin engagement. Osteoclasts cultured with M-CSF and
RANKL for four days were detached and either maintained in
suspension or layered on vitronectin coated plates for 30 min.
Hyper-phosphorylation of both kinases was observed in the
Sema4D 2/2 osteoclasts, either maintained in suspension or
adherent as if they were constitutively active in the mutant cells
(Fig. 2E). We sought to determine whether further aVb3 down-
stream signalling was also perturbed. Rac1-GTPase regulates
cellular actin-dynamics, and it is the downstream target of aVß3
induced cytoskeleton reorganization in osteoclasts [20]. In
accordance with c-Src and Pyk2 hyper-phosphorylation, we found
that the Rac1-GTP content was higher in Sema4D 2/2
osteoclasts, regardless of the substratum (Fig. 2F), whereas the
GTP-bound Rac1 level in steady-state osteoclasts was similarly low
in both WT and Sema4D 2/2. In summary, a Sema4D deficiency
in primary osteoclasts led to reduced resorption activity, in part
due to dysfunction of the adhesion properties and an unbalanced
regulation of ß3 integrin sub-unit signaling.
Sema4D deficiency leads to high bone mass phenotype
due to decreased bone resorption in sexually mature
female mice
To determine if Sema4D has a function in bone, we first
analyzed Sema4D-deficient mice using histomorphometry. In 3-
month-old female vertebrae, quantification of the trabecular bone
volume revealed a 33% increased bone mass in Sema4D-deficient
mice compared to WT (Fig. 3A). Bone structure was also modified,
the thickness of the trabeculae being unaffected, while the number
of nodes and the trabecular spacing were significantly lower in
Sema4D-deficient mice compared to WT, indicating that the
number, but not the size, of the trabeculae was modified in the
Sema4D-deficient mice (Fig. 3B). We then tested resorption
parameters in vivo. Deoxypiridinoline crosslinks (DPD) were
decreased in the Sema4D-deficient mice when compared to their
WT littermates, showing that the increased bone mass resulted, at
least in part, from decreased bone resorption (Fig. 3D). Neither the
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vitro. A–D) Sema4D expression and localization. A/ QPCR analysis showing an increase of Sema4D expression along the osteoclast differentiation
pathway, B/ Total cell extract, either from primary calvaria derived osteoblast cultures or from osteoclasts isolated from WT or Sema4D-deficient mice,
were immunoblotted using an anti-Sema4D specific antibody. Sema4D is present in WT osteoclasts. a-tubulin was used as loading control. C/ FACS
analysis on non-permeabilized pre-osteoclasts shows that Sema4D is expressed at the WT cell surface but not in Sema4D 2/2 cells. D/ Mature
osteoclasts were fixed and immunolabeled with anti-Sema4D or anti-ß3 integrin chain antibodies. Merge picture and inset show that Sema4D partially
colocalized with the ß3 integrin chain (bar: 10 mm). E–G) Sema4D 2/2 osteoclast progenitors differentiation and proliferation rate. E/ Bone marrow
precursor cultured for either 4 or 5 days in the presence of MCSF and RANKL. Cultures were then stained for TRAP activity and TRAP positive
multinucleated cells formed were counted. This showed that the formation of TRAP positive multinucleated osteoclasts from Sema4D 2/2
precursors was reduced compared with WT. F/ Bone marrow precursors were cultured in the presence of MCSF to assess proliferation of progenitor
cells. At each time point, the cells were fixed and stained with crystal and the 590 nm OD measured, reflecting the cell number. This shows that
Sema4D 2/2 precursors proliferate more slowly than their WT counterparts during the growth phase. G/ To confirm that the delay in Sema4D 2/2
osteoclast formation could be due to their impaired proliferation rate, 20% more Sema4D 2/2 bone marrow precursors (375 cells/mm
2) were seeded
than WT (312 cells/mm
2) in the presence of M-CSF and RANKL. Mature multinucleated TRAP positive osteoclasts were counted on day 5. Similar
osteoclast counts were obtained in both cultures and they displayed the same degree of multinucleation. Error bars represent SEM, *** indicate a p
value#0.001.
doi:10.1371/journal.pone.0026627.g001
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Sema4D-deficient mice, showing that the decreased bone resorp-
tion observed in Sema4D-deficient mice was due to a functional
defect in the osteoclasts (Fig. 3C). On the other hand, the
measured cellular and dynamic bone formation parameters were
similar in Sema4D-deficient and WT mice (Fig. S1A–B). Altogether
these data show that Sema4D is indeed a physiological regulator of
bone resorption, without affecting bone formation.
Figure 2. Sema4D 2/2 osteoclasts resorb less than WT and display an altered signaling of ß3 integrin sub-unit mediated adhesion.
F/ A/ Resorption tests: osteoclasts were seeded on apatite collagen complex (ACC) coverslips or on plastic. 24 hours after seeding, TRAP staining was
performed to assess the number of multinucleated osteoclasts (3 or more nuclei). ACC coverslips were then stained with silver nitrate to measure the
percentage of resorbed area (white) versus the total area with ImageJ software micrographs are representaive of several independent experiments. B/
The migration speed of resorbing osteoclasts on ACC was measured by videomicroscopy, followed by software-assisted quantification. C/ Cell
spreading ability was assessed by seeding WT and Sema4D-deficient osteoclasts on vitronectin- coated coverslips for the stated time. D/ The F-actin
content was labeled with 488-Alexa-Phalloidin and the surface area measured using ImageJ software. Results are representative of 3 independent
experiments, n$150 (n=cell number per time point). Error bars represent SEM; * p#0.01; ** p#0.001; *** p#0.0001. E/ Hyperphosphorylation of
Pyk2 and c-Src in Sema4D 2/2 osteoclasts compared to WT. Osteoclasts were detached and either maintained in suspension (S) or plated on
vitronectin for 30 min and lysed. The Pyk2 and c-Src phosporylation levels were revealed on total cell lysates by immunoblotting with anti-P-Pyk2 or
anti-P-c-Src antibodies. This shows hyperphosphorylation of Pyk2 and c-Src in Sema4D 2/2 osteoclasts compared to WT. Increased Rac1 activity in
Sema4D 2/2 pre-osteoclasts versus WT. F/ Four-hour-starved pre-osteoclasts were lifted and replated either on plastic (P) or Apatite Collagen
Complex (ACC). 1 hour post-adhesion, cells extracts were pulled down for the GTP-bound Rac1 content. Rac1-GTP and total Rac1 were detected by
immunoblotting and the corresponding signals were densitometrically quantitated, for steady state analysis, no treatment was applied to cells prior
the GTP-Rac1 pull down. Results are representative of at least 3 independent experiments.
doi:10.1371/journal.pone.0026627.g002
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mice is gender dependent and is not osteoclast
autonomous
We further analyzed the bone phenotypes of WT and Sema4D-
deficient females at earlier and later stages (1 and 6 months). These
analyses revealed that the bone resorption phenotype was only
present in sexually mature females, since 6-month-old females had
increased bone mass similar to the 3-month-old mice, while 1-
month-old Sema4D-deficient females had normal bone mass
(Fig. 4A). On the other hand, 3-month-old Sema4D-deficient males
had similar bone mass than their WT littermates (Fig. 4A). Those
observations questioned the assumption that the bone phenotype
observed in Sema4D 2/2 animals relied on an osteoclast-related
intrinsic defect. To answer this question, we performed Sema4D
2/2 or WT bone marrow cross transplants in WT and Sema4D-
deficient mice, following lethal doses of gamma radiation leading
to hematopoietic lineage depletion, including that of osteoclasts.
The results of these bone marrow cross transplants revealed that
the bone phenotype of the transplanted mice did not depend on
the donor genotype but on genetic background of the transplanted
mice. Indeed, Sema4D-deficient mice had a higher BV/TV than
the WT mice, whether they have been grafted with Sema4D-
deficient or WT osteoclasts (Fig. 4B). Similarly, urinary DPD levels
were higher in Sema4D 2/2 recipient mice than in the WT mice
regardless of the graft genotype (Fig. S2). Thus, this unexpected
result showed that the Sema4D 2/2 bone resorption phenotype is
not secondary to an osteoclast-specific defect. In other words, the
functional defects of Sema4D 2/2 osteoclasts that we observed in
vitro are either too mild to be detected in vivo or are compensated
for in vivo. Defective activities of osteoclasts lacking Sema4D have
revealed an altered ß3 integrin sub-unit down-stream signaling,
suggesting a common pathway for both proteins and a functional
cross talk. To test this latter hypothesis, we transduced BMMs
derived either from WT or Sema4D 2/2 mice, with empty
retroviruses (PMX) or retroviruses expressing the full-length ß3
cDNA. After antibiotic selection, mature osteoclasts were
differentiated and their ability to resorb mineralized matrix
assessed. Over expression of the integrin ß3 chain in Sema4D 2/
2 osteoclasts rescued their deficiencies. Indeed, integrin ß3
transduced Sema4D 2/2 osteoclasts were able to resorb mineral
matrix to the same extent as WT osteoclasts (Fig. 4C). These
results show that the integrin ß3 chain over expression can
compensate for Sema4D 2/2 osteoclast resorption defects at least
in vitro and indicate that Sema4D regulates bone resorption by an
indirect mechanism in vivo.
Reproductive defect in Sema4D-deficient mice
While characterizing the origin of the Sema4D 2/2 mice high
bone mass phenotype, we noticed that these mice produced fewer
pups than WT, suggesting that Sema4D 2/2 mice were less fertile.
Quantification of both the number of pups per brood and the
number of litters per breeding period confirmed the decreased
reproductive ability of Sema4D-deficient mice (Fig. 5A–D). We
then asked how the Sema4D deficiency influenced the decreased
fertility observed in these mice. It has been reported that deletion
of Sema4D receptor plexinB1 (PlexB1) leads to a reduced number
of Gnrh1 secreting neurons in adult mice hypothalamus. We
speculated though that Sema4D-deficient mice might present a
Figure 3. High bone mass and functional bone resorption defect in 3-month-old Sema4D-deficient females. A/ Bone volume and bone
micro architecture parameters of 3-month-old WT and Sema4D-deficient mice were measured on vertebrae sections stained with von Kossa/Van
Gieson stain. B/ B.V./T.V., bone volume/tissue volume; Tb.Th., trabecular thickness; N.Nd., number of nodes, Tb.Sp.; trabecular spacing n$10 for both
genotype. C/ In vivo quantification of osteoclast numbers and sizes of 3-month-old female vertebral sections stained for TRAP activity and with alcian
blue, revealed that osteoclast differentiation is not affected in the absence of Sema4D. (N.Oc./B.Pm., number of Oc per bone perimeter; Oc.S./B.S., Oc
surface per bone surface; N.Oc./Oc.Pm number of Oc per Oc perimeter) n=8 for both genotypes. D/ Urinary deoxypyridinoline (DPD) cross-links
elimination was significantly lower in Sema4D 2/2 animals compared to WT, indicating that the Sema4D deficiency results in a functional decrease in
bone resorption n=8 for WT and n=14 for Sema4D2/2 mice. Error bar represents SEM; *** indicate a p value#0.0001 between two groups.
doi:10.1371/journal.pone.0026627.g003
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reduction in the Gnrh1 transcript level in the hypothalamus of
Sema4D 2/2 mice, whereas no variation was observed in frontal
brain used as a tissue control (Fig. 5D). As gonadotropin-hormone
releasing hormone-1 (Gnrh1) is involved in the hypothalamic-
pituitary-ovarian axis, we then wondered if the decreased
expression of Gnrh1 could result in impaired ovarian function,
which could explain the decreased fertility observed in Sema4D 2/2
mice. We compared the morphological follicles organization and
counted the number of classified follicles in the ovaries of mutant
versus WT mice. Analysis of histological ovary sections showed a
significant reduced number of secondary follicles in the Sema4D 2/2
mice (Fig. 5E). On the other hand, ovary and uterus weights were
similar in three-month-old Sema4D 2/2 females, compared to their
WT counterparts (Fig. S3A–B). Accordingly, we did not find any
significant variations in the basal levels of estradiol (E2) (Fig. S3B).
Altogether our results show that Sema4D deficiency is required for
proper female reproductive function.
Figure 4. In vivo increased bone mass in Sema4D 2/2 mice is not due to an osteoclast defect. A/ Bone volume measurement of 1-month-
old female and of 3-month-old male vertebrae by histomorphometrical analysis (respectively: n=9 and n=11 for WT; n=9 and n=12 for Sema4D2/2
mice), and of 6-month-old femurs by microCT (n=12 for WT and n=9 for Sema4D2/2 mice), revealed that the high bone mass phenotype of Sema4D
2/2 mice is only present in sexually mature females, but not in males. B/ 2-month-old Sema4D 2/2 and WT littermates received lethal doses of c
radiation and were subsequently transplanted with Sema4D 2/2 or WT bone marrow. The bone volume of female femurs was measured by
histomorphometry 1 month after transplantation (i.e. in 3-month-old mice) n=12 per group. C/ Defective resorption of Sema4D2/2 osteoclasts is
compensated by integrin ß3 chain overexpression. Micrographs of a representative experiment show the mineralized resorbed surfaces by transduced
osteoclasts. The histogram shows that ß3 integrin chain over-expression in Sema4D 2/2 osteoclasts could rescue their resorption defects. Results
represent the mean of two independent experiments (four ACC coverslips were used for each conditions). Total protein lysates of infected osteoclast
progenitors were analyzed by western blotting for their ß3 integrin sub-unit content. It shows hß3 integrin expression in lanes Int ß3 compared to lanes
corresponding to empty vector PMX transduced cell extracts. Equal loading was assessed by tubulin.
doi:10.1371/journal.pone.0026627.g004
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female reproductive function
The bone marrow transplant experiment demonstrated that the
bone resorption defect observed in Sema4D 2/2 mice did not
result in an intrinsic osteoclast defect (Fig. 4B). Moreover this
phenotype was observed only in sexually mature Sema4D 2/2
females, but not in males and the Sema4D 2/2 reproductive
function was impaired (Fig. 4A and 5A–C). Altogether these results
strongly suggested that the Sema4D bone resorption defect was
dependent on ovarian function. To confirm this assertion, we
ovariectomized 2-month-old Sema4D-deficient females and ana-
lyzed their bone phenotype one month later. As expected, WT
ovariectomized mice had a lower uterine weight and lost about
20% of their tibial trabecular bone mass as a result of an increased
bone resorption (Fig. 6A–B and S2A). On the other hand,
following ovariectomy, Sema4D-deficient mice showed a 45%
increase in bone resorption than WT mice (Fig. 6B). As a result,
Sema4D 2/2 ovariectomized females had similar bone volumes to
those of the WT ovariectomized females (Fig. 6A). The
observation that the phenotype is osteoclast independent but sex
dependent, together with impaired reproductive function, strongly
suggests that the Sema4D 2/2 resorption phenotype is directly
linked to ovarian function.
Discussion
Although semaphorins were first identified as axon guidance
cues, they have since, been shown to be important regulators of a
wide variety of biological functions. The present study has
uncovered new functions for semaphorin 4D as a regulator of
bone resorption both in vitro and in vivo.
In vitro, Sema4D 2/2 osteoclasts are unable to resorb
mineralized matrix properly and this defect is, at least in part,
due to altered adhesion ability and subsequently to a migration
defect. Remarkably these features are similar to those observed in
integrin ß3 2/2 osteoclasts, such as defective adhesion, spreading
and bone resorption [16]. Together with those similarities, we
found that Sema4D deficiency in osteoclasts leads to sustain
phosphorylation of components of the adhesion complex (Pyk2
and c-Src) (Fig. 2E). This also affects the activity of the
downstream effector Rac-1 (Fig. 2F). Moreover, Sema4D 2/2
defective resorption is rescued by integrin ß3 chain over-
expression.Thus our data show for the first time that Sema4D
can act as a modulator of aVß3 integrin downstream signaling in
osteoclasts and suggest functional cross-talk between ß3 integrin and
Sema4D (Fig. 4C). This might be a general property of Sema4D.
Notably, Sema4D and ß3 integrin are co-expressed in platelets and it
is conceivable that the functional crosstalk between ß3 integrin and
Figure 5. Sema4D deficiency decreases fertility and modifies the hypothalamic-pituitary-ovarian axis. A–C/ Monitoring of mating
revealed a statistically significant decrease, in the number of litters per mother, of viable litters and the average number of pups per mother (number
of cages n=7 for WT and 11 for Sema4D 2/2; performed twice). D/ Gnrh1 expression in the Sema4D 2/2 adult female brain. Total mRNA was
extracted either from total brain or hypothalamus of 3 month-old WT and mutant females. Sema4D 2/2 Gnrh1 transcript levels were monitored by
real time PCR and expressed as fold difference to the WT level, n=4. E/ Morphological classification and quantification of follicles based on granulosa
cell layers. Arrows indicate primordial or primary follicles containing an oocyte surrounded by a layer of granulosa cells. Graph shows the average
number of follicles over 9 sections of each phenotype (n=8).
doi:10.1371/journal.pone.0026627.g005
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recent study reported that such a crosstalk between Sema4D and
aIIB ß3 integrin takes place for thrombus formation by platelets
[21].
In apparent agreement with the in vitro data showing functional
defects in osteoclasts, we report that Sema4D-deficient females
present a high bone mass phenotype linked to defective bone
resorption. Histomorphometrical data show a functional rather
than a differentiation defect of the osteoclasts in Sema4D-deficient
females, since their osteoclast numbers and sizes did not differ
from WT (Fig. 3B–C). However, this phenotype was gender
specific, and only observed in sexually mature females. In addition,
bone marrow cross transplant experiments confirmed that the
decreased bone resorption in vivo was not due to an intrinsic defect
in the osteoclasts (Fig. 4A–B). The discrepancy between our in vitro
and in vivo data indicates that the functional defect of Sema4D 2/2
osteoclasts might be compensated for in vivo and that, unexpect-
edly, Sema4D controls bone mass mostly through an indirect
pathway. Two non-exclusive mechanisms could explain these
differences. First, our data suggest a functional cross-talk between
ß3 integrin and Sema4D as it modulates ß3 integrin intracellular
signaling, although they do not interact directly (data not shown).
It is thus conceivable, that the Sema4D osteoclast-specific effect
could be compensated, at least partially, in vivo, by ß3 integrin sub-
unit. Second, in vivo Sema4D 2/2 high bone mass phenotype is
dependent on mice hormonal status that dominates over the
osteoclast intrinsic resorption defect. Therefore, the bone resorp-
tion defect observed in Sema4D-deficient mice is the result of an
indirect mechanism.
In addition to the bone phenotype, we observed that
reproduction is impaired in Sema4D-deficient mice, revealing a
new physiological function of Sema4D. Our data showed that the
Sema4D2/2 defective gonadal function could, at least in part, be
explained by a significant decrease in Gnrh1 hypothalamic
expression and reduced ovarian follicle maturation (Fig. 5D–E).
These latter results obtained from the analysis of Sema4D2/2
mice abnormalities strengthen two recent reports showing that
Sema4D is indeed involved in hypothalamic-hypophyseal-ovarian
axis development. First, ex vivo, Sema4D is implicated in mouse
ovary follicular development [14]. Second, analysis of Sema4D
receptor PlexinB1-deficient mice phenotype revealed that PlexinB1
depletion results in a reduction of Gnrh1secreting neuron in mice
adult brain due to a defective Sema4D induced neuron migration
[12].
On the other hand no change was detected in Sema4D 2/2
mice body or uterine weights, in accordance with the fact that
these mice have similar E2 blood basal levels as WT mice (Fig.
S3A–B). Although no hypogonadism was detected in Sema4D 2/
2 mice, they presented a decreased fertility. This observation
reminds of clinical cases in women, in which primary ovarian
deficiencies were observed along with normal E2 blood levels
[22,23]. Although we measured normal basal E2 blood level found
in Sema4D 2/2 mice, we cannot also exclude a fine deregulation
of E2 cycles. Alternatively, it is also possible that other hormones
from the ovarian axis might explain the reproductive function
defects and the secondary bone phenotype. Indeed, contribution
of other than E2 hypothalamic-hypophyseal-ovarian axis hor-
mones to bone mass regulation has largely been established
[1,24,25]. For instance, it has been demonstrated that FSH
directly regulate bone mass independently of E2 by activating
bone resorption and therefore it might be a potential factor
involved in Sema4D 2/2 bone resorption phenotype [24]. In the
same way, we did not completely rule out the possibility that Gnrh1
could act directly on osteoclasts, to promote bone resorption,
although it has been shown that Gnrh1 have no effect on
osteoclastogenesis [24] and that hypogonadism is currently
associated with bone loss [26]. In addition to the FSH direct
effect on bone, recent studies have reported that elevated FSH
Figure 6. Increased bone mass in Sema4D 2/2 mice depends on ovarian function. A/ Bone volume quantification of 3-month-old Sema4D
2/2 and WT mice vertebrae one month after ovariectomy or sham surgery. B/ Quantification of urinary deoxypyridinoline residues from 3-month-old
Sema4D 2/2 and WT mice, one month after ovariectomy or sham surgery show greater increases in bone resorption in Sema4D 2/2 than in WT,
(n=8). Error bar represents SEM; * p#0.01; ** p#0.001; *** p#0.0001.
doi:10.1371/journal.pone.0026627.g006
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increased bone formation is correlated to the FSH induced
ovarian secretion of inhibin and androgens [27]. There are
accumulating evidences showing that gonadal factors, such as
inhibins, would regulate bone remodeling either acting on bone
formation if their mode of exposure is continuous or bone
resorption if it secreted in a cycling mode [28]. This complex
endocrine regulation of bone mass by the inhibins can also be
observed in woman prior to menopause [29,30]. Thus inhibins
might also be good candidates to play a role in the indirect
regulation of bone mass by Sema4D.
Nevertheless, we have shown the dependence of the Sema4D 2/2
mice bone resorption phenotype on ovarian functions. Beside the
gender specificity of the bone resorption phenotype, we found that
the ovariectomy of sexually mature Sema4D 2/2 females abrogates
the bone phenotype. This result clearly demonstrates the absolute
requirement of mature ovaries to observe the bone phenotype in
Sema4D-deficient female mice (Fig. 6A–B). In summary, our present
study demonstrates first that in vitro the defective resorption activity of
sema4D2/2 osteoclast is due to dysfunction of adhesion and
migration properties reflected by an hyperphosphorylation of
ß3integrin sub-unit down-stream effectors. Secondly, we provide
evidence that the observed high-bone mass phenotype of Sema4D2/
2 female mice is due to a functional defective resorption. We show
that this in vivo effect of Sema4D on bone resorption does not result
from an osteoclast-specific defect but is rather dependent on the
ovarian function by an as-yet-undefined pathway. Thus Sema4D is an
indirectregulator of bone resorption that actsthrough its effecton the
reproductive system in females. In conclusion, Sema4D is a factor




LSM (Lymphocyte Separation Media) and RNA-Now were
purchased from Eurobio. a-MEM and fetal calf serum were from
Invitrogen and Biowest, respectively. Ascorbic acid, sodium b-
glycerophosphate, culture cell BSA and Leukocyte acid phospha-
tase kit for TRAP staining were from SIGMA. Vitronectin was
purchased from BD Biosciences. RNeasy Kit, Quantitec primer
assay and Mix-Quantitect SYBR Green were from Qiagen. I-
ScripTM cDNA synthesis Kit was from BioRad. Antibodies: anti-
Sema4D antibodies were BMA12, Abm30 clones and CD16/32
(clone2.4G2) respectively from Cliniscience and BD Biosciences.
Anti-P-Pyk2 was from Biosource, anti-P-cSrc (Y-416) from Cell
Signaling. Anti-cSrc, , goat anti ß3 integrin, was purchased from
Santa-Cruz and hamster anti ß3 integrin from BD pharmingen.
Secondary antibodies, mouse and rat IgGs were from Jackson.
The RNeasy Kit, Quantitec primer assay (QT 01062600) and
Mix-Quantitect SYBR Green were from Qiagen. I-ScripTM
cDNA synthesis Kit was from BioRad. Pyrilinks-D immunoassay
and creatinin kits were used according to the manufacturer Quidel
Corporation’s protocols. E2 levels we measured by EIA from 2
consecutive days collected blood samples (Cayman, Chemical).
Statistical differences between groups were assessed using t-tests.
Mice
Sema4D-deficient mice were described in [18], were backcrossed
with C57BL/6 mice. Background strain characterization by
Charles Rivers genetic testing services indicated that 89,43% of
the 110 tested markers were specific of the C57Bl6 background.
All mice were maintained in our animal facility and cared for in
accordance with institutional guidelines for animal welfare
(Approval was given by ‘‘the comite ´ regional d’e ´thique pour
l’expe ´rimentation animale’’ on May 06 2008) with the register
approval number 0265). For the induced sex hormone deficiency,
8-week-old female mice underwent ovariectomies (ovx), whereas
the controls consisted of sham-operated mice (sham).
Statistical differences between groups were assessed using t-tests.
Primary osteoblast cultures from calvaria
Osteoblasts were isolated from enzymatically dissociated
calvaria from 3-day-old mice and were plated in differentia-
tion medium: a-MEM) containing 10% heat-inactivated serum
50 g/ml ascorbic acid and 10 mM sodium ß-glycerophosphate.
After 24 h, the cells were harvested using 0.01% trypsin in PBS
and the cells were plated at 20 cells/mm
2 and grown for 22 days in
the same differentiation medium (replaced every two days).
Primary osteoclast cultures
Bone marrow mononuclear cells from 8-week-old WT or
Sema4D 2/2 mice were cultured at 500cells/mm
2 for 5 to 6 days
in the presence of a-MEM containing 10% (v/v) fetal calf serum,
M-CSF (20 ng/ml) and GST-RANKL (30 ng/ml) [31]. We
designated as pre-osteoclasts, cells containing 2 to 3 nuclei,
obtained after 3 days of culture, whereas osteoclasts were
multinucleated cells showing 5 to 10 nuclei and mature osteoclasts
were large multinucleated cells with a high number of nuclei
(n$10). TRAP activity in cells was assessed after staining with
leukocyte acid phosphatase kit (Sigma).
Quantification of proliferation
At each time point cells seeded on multi-well plates are fixed in
1,1% glutaraldhedyde for 15 min and washed twice in water and
air dried. Prior lysis in acetic acid 10%, cells are stained in crystal
violet 0,1% for 20 min, washed and air dried, plates are read at
OD 590 nm for quantification.
Adhesion and spreading assay
For in vitro spreading assays, osteoclasts were detached with
0.02% EDTA in PBS and washed twice with a-MEM containing
10 mM Hepes and 0.1% culture cell BSA. They were kept in
suspension for 2 hours at 37uC and then either maintained in
suspension or plated on 5 mg/ml vitronectin-coated dishes,
according to the manufacturer’s instructions. At the stated time,
cells were lysed, and an equal amount of protein was analyzed by
Western blotting.
For the spreading assay, osteoclasts were seeded on 5 mg/ml
vitronectin pre-coated cover slips for 5, 10, 15 or 30 min and fixed
with 4% PFA, permeabilized and F-actin labeled with 488-Alexa-
Fluor phalloidin. Cells were imaged with a planNeofluar 206
objective (NA 0.5) using a Zeiss axioplan microscope. The surface
area was automatically measured with ImageJ software, using an
ImageJ plug-in developed by our imaging facility (Platim IFR128).
BMMs retroviral infection
PMX derived retroviral particles were produced in Plat-E
retroviral packaging cells (Cell Biolabs). In parallel PMX -IRES-
GFP retrovirus (from Dr. T. Kitamura –Tokyo) was produced
using the same conditions to be able to visualize and follow
transfection and infection under an inverted microscope. Briefly,
on day 1, PMX DNA constructs (PMX empty, or expressing
human integrin ß3 chain) were transfected in Plate-E cells with
Fugen 6 (Roche), on day 2 fresh media was added. The media was
collected on day 4 and centrifuged to remove the cell debris. M-
CSF (20 ng/ml) and 8 mg/ml of polybrene (Sigma) were added to
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mononuclear cells prepared on day 3 in presence of MEM 10%
FCS and 25 ng/ml of M-CSF. The following day, the inoculum
was removed and the transduced cells were subjected to blasticidin
selection (1 mg/ml) for 2 days in presence of MEM 10% FCS and
20 ng/ml of M-CSF. Then medium was replaced by classical
osteoclast differentiation medium (MEM 10% FCS 20 ng/ml of
M-CSF and 30 ng/ml of RANK-L for an additional 3days before
lifting and seeding the mature osteoclasts on mineral for 24 h [32].
Cell transfer experiments
Two-month-old wild-type or Sema4D 2/2 mice were irradiated
with lethal doses of gamma radiation (10 Gray) and reconstituted
with a retro-orbital injection of 1 million bone marrow cells
derived from wild-type or Sema4D 2/2 mice, un-transplanted
mice died after 10 days. One month after grafting, the mice were
sacrificed for bone analysis.
Histology and histomorphometric analyses
Non-decalcified bones were embedded in methyl methacrylate,
before being stained for Von Kossa, TRAP staining or histological
analysis. Mice were injected with 100 ml of a 5 mg/ml of a calcein
solution, 6 and 2 days before sacrifice and were processed for
plastic embedding, as previously described [33]. Measurements
were performed with the OsteoMeasure Analysis System (Osteo-
metrics) using a 3CCD color video DXC-390camera (Sony)
coupled to a Leica microscope, according to standard procedure
[34].
Morphological classification of follicles
Three-month-old females were sacrificed. Frozen ovaries were
sectioned and hematoxylin stained. Results were obtained through
averaging all serial sections (200 mM). Follicles were classified
according to Myers [35].
RNA extraction and RT-PCR
Real-time RT-PCR was performed using the MXP-3000P
PCR-system (Stratagene). Samples were run in triplicate and the
cycle parameters were 95uC for 15 min, followed by 40 cycles at
95uC for 30 s, 55uC for 30 s and 72uC for 30 s. Gene expression
levels were calculated using the DDCt method. Expression was
normalized using the mouse ribosomal gene (Rps17).
Statistical analysis
Statistical differences were analyzed with Student’s t-test and
error bars represent SEM. Values of P#0,01 were considered
significant. * p#0.01; ** p#0.001; *** p#0.0001 when not
otherwise specified.
Supporting Information
Figure S1 A/ Cellular and B/ Dynamic bone formation
parameter measurements using alcian blue and double calcein
labeling, respectively, show an absence of bone formation defects
in 3-month-old Sema4D 2/2 females compared to their WT
littermates. (N.Ob./B.Pm., number of Ob per bone perimeter;
Ob.S./B.S. Ob surface per bone surface; BFR, bone formation
rate; MAR, mineral apposition rate; M.S./B.S., mineralized
surface per bone surface). Error bar represents SEM, *** indicate
a p value#0.001 between two groups (n=12).
(TIF)
Figure S2 Urinary DPD measurement of 3-month-old Sema4D
2/2 and WT irradiated mice one month after transplantation
(n=10 for WT and n=12 for Sema4D2/2 respectively).
(TIF)
Figure S3 A/ Uterine weight of 3-month-old Sema4D 2/2 and
WT mice: after ovariectomy or sham surgery (n=7 and 8
respectively). B–C/ No significant differences were observed in
ovary weight and estradiol levels in 3 month-old females (n=8 and
n=20 respectively). Error bar represents SEM, *** p#0.005.
(TIF)
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